Tissue Regenix has published a trading update for the 6-months to June 2025. The company expects group revenues to be down 6% YoY to $13.8m and to report a positive adjusted EBITDA, reflecting uncertain economic conditions and regulatory approvals impacting the ability to win new customers in new markets. Tissue Regenix expects to achieve FY25 adjusted EBITDA in-line with that for FY24A of $1.9m and states its cash position at the close of the period is sufficient to support the business’s curre ....
